UP!

PTCT $52.01

PTCT target price
52.01
0
0
PTC Therapeutics, Inc.
Type
Public
Traded as NASDAQ: PTCT
Industry Pharmaceuticals
Headquarters South Plainfield, New Jersey, United States
Website ptcbio.com

Coordinates: 40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W / 40.550722; -74.423071

PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs that regulate gene expression by targeting post-translational control (PTC) mechanisms in orphan diseases.

Since 2003, PTC has been working on a drug for Duchenne muscular dystrophy.

In September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases.

As of May 2016, PTC portfolio includes small-molecule compounds for treatment of spinal muscular atrophy (RG7916) and Duchenne muscular dystrophy (Ataluren and another exon skipping compound).


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-26 Future report Set alerts
Q2 2022 2022-08-04 -2.13 -2.13
Q1 2022 2022-05-03 -1.78 -1.78
Q4 2021 2022-02-22 -2.03 -2.03
Q3 2021 2021-10-28 -1.89 -1.89
Q2 2021 2021-07-29 -1.68 -1.68
Q1 2021 2021-05-04 -1.83 -1.83
Q4 2020 2021-02-25 -1.08 -1.08
Q3 2020 2020-10-29 0.00 0.00
Q2 2020 2020-08-05 -2.78 -2.78

Ratings

2016-05-06 Reiterated Rating Jefferies Group Hold $8.00
2016-05-06 Reiterated Rating Credit Suisse Buy
2016-05-06 Reiterated Rating Credit Suisse Group AG Buy
2016-04-18 Reiterated Rating RBC Capital Sector Perform $9.00
2016-04-18 Reiterated Rating Royal Bank Of Canada Sector Perform $9.00
2016-04-17 Reiterated Rating Oppenheimer Buy $39.00
2016-04-17 Reiterated Rating Cowen and Company Hold
2016-04-17 Reiterated Rating Oppenheimer Holdings Inc. Buy $39.00
2016-03-23 Reiterated Rating Wedbush Neutral $11.00
2016-03-01 Lower Price Target Jefferies Group Hold $12.00 to $8.00
2016-03-01 Downgrade Cowen and Company Outperform to Market Perform
2016-03-01 Downgrade Wedbush Outperform to Neutral $27.00 to $11.00
2016-03-01 Reiterated Rating Credit Suisse Outperform $36.00 to $12.00
2016-03-01 Boost Price Target Barclays Overweight $40.00 to $100.00
2016-03-01 Boost Price Target RBC Capital Sector Perform $9.00 to $11.00
2016-03-01 Boost Price Target Barclays PLC Overweight $40.00 to $100.00
2016-02-29 Reiterated Rating Oppenheimer Buy $111.00 to $39.00
2016-02-29 Downgrade Bank of America Buy to Neutral
2016-02-29 Downgrade Bank of America Corp. Buy to Neutral
2016-02-24 Lower Price Target Wedbush Outperform $65.00 to $27.00
2016-02-24 Downgrade Citigroup Inc. Buy to Neutral $90.00 to $13.00
2016-02-24 Upgrade Jefferies Group Underperform to Hold $18.00 to $12.00
2016-02-24 Downgrade RBC Capital Outperform to Sector Perform $56.00 to $11.00
2016-02-24 Reiterated Rating Cowen and Company Outperform $120.00
2016-02-23 Reiterated Rating Oppenheimer Buy $135.00 to $111.00
2016-02-23 Downgrade JPMorgan Chase & Co. Overweight to Neutral $81.00 to $22.00
2016-02-08 Reiterated Rating Cowen and Company Outperform $120.00
2016-02-01 Reiterated Rating Oppenheimer Outperform $135.00
2016-01-19 Initiated Coverage Credit Suisse Outperform $36.00
2016-01-07 Reiterated Rating Wedbush Outperform $65.00
2016-01-05 Reiterated Rating Oppenheimer Outperform $135.00
2015-12-21 Reiterated Rating Oppenheimer Buy $135.00
2015-11-25 Downgrade Jefferies Group Hold to Underperform $26.00 to $18.00
2015-11-23 Reiterated Rating Oppenheimer Outperform $135.00
2015-11-12 Reiterated Rating Cowen and Company Outperform $120.00
2015-11-11 Reiterated Rating Oppenheimer Outperform $135.00
2015-10-22 Initiated Coverage Jefferies Group Hold $26.00
2015-10-18 Reiterated Rating Barclays Buy $100.00
2015-10-17 Reiterated Rating Oppenheimer Buy
2015-10-16 Lower Price Target Wedbush Outperform $81.00 to $65.00
2015-10-16 Reiterated Rating JPMorgan Chase & Co. Overweight $100.00 to $84.00
2015-10-16 Lower Price Target Oppenheimer Outperform $155.00 to $135.00
2015-10-16 Lower Price Target RBC Capital Outperform $85.00 to $56.00
2015-10-16 Reiterated Rating Roth Capital Hold $63.00
2015-10-01 Reiterated Rating Oppenheimer Outperform $155.00
2015-09-20 Reiterated Rating Oppenheimer Outperform $155.00
2015-09-18 Downgrade Roth Capital Hold
2015-08-25 Initiated Coverage Citigroup Inc. Buy $90.00
2015-08-23 Reiterated Rating Roth Capital Neutral
2015-08-03 Reiterated Rating Roth Capital Hold
2015-07-31 Boost Price Target RBC Capital Outperform $81.00 to $85.00
2015-07-15 Upgrade JPMorgan Chase & Co. Neutral to Overweight $74.00 to $100.00
2015-07-10 Reiterated Rating Roth Capital Neutral $63.00
2015-06-24 Set Price Target Oppenheimer Buy $155.00
2015-06-17 Reiterated Rating Deutsche Bank Buy $115.00
2015-06-17 Reiterated Rating Deutsche Bank AG Buy $115.00
2015-06-11 Reiterated Rating RBC Capital Outperform $91.00
2015-05-06 Reiterated Rating Deutsche Bank Buy $115.00
2015-05-05 Reiterated Rating Credit Suisse Outperform $100.00
2015-05-05 Set Price Target Oppenheimer Buy $155.00
2015-05-05 Downgrade Roth Capital Buy to Neutral $75.00 to $63.00
2015-04-24 Reiterated Rating RBC Capital Outperform $81.00
2015-04-23 Boost Price Target Oppenheimer Outperform $135.00 to $155.00
2015-04-16 Upgrade Cowen and Company Market Perform to Outperform
2015-04-09 Boost Price Target Deutsche Bank Buy $75.00 to $115.00
2015-03-03 Initiated Coverage Barclays Overweight $100.00
2015-03-02 Boost Price Target Wedbush $81.00
2015-03-02 Downgrade JPMorgan Chase & Co. Overweight to Neutral
2015-03-02 Boost Price Target Roth Capital Buy $58.00 to $75.00
2015-02-24 Reiterated Rating Deutsche Bank Buy
2015-02-24 Boost Price Target Credit Suisse $100.00
2015-01-22 Set Price Target Deutsche Bank Buy $75.00
2015-01-22 Initiated Coverage RBC Capital Outperform $81.00
2014-12-23 Initiated Coverage Wedbush Outperform
2014-12-18 Initiated Coverage Citigroup Inc. Buy $81.00
2014-12-04 Upgrade Credit Suisse Top Pick
2014-11-07 Set Price Target Credit Suisse Outperform $55.00 to $66.00
2014-10-13 Reiterated Rating Bank of America Buy $50.00 to $48.00
2014-10-06 Downgrade Cowen and Company Outperform to Market Perform
2014-09-29 Reiterated ROTH Capital Buy $43 to $58
2014-09-29 Boost Price Target Roth Capital Buy $43.00 to $58.00
2014-09-24 Boost Price Target Credit Suisse Outperform $40.00 to $55.00
2014-09-23 Reiterated Rating Bank of America Buy $37.00 to $50.00
2014-09-15 Initiated Coverage Deutsche Bank Buy $75.00
2014-08-18 Boost Price Target Roth Capital Buy $34.00 to $43.00
2014-07-31 Initiated Coverage Oppenheimer Outperform $60.00
2014-07-22 Initiated Coverage Bank of America Buy $37.00
2014-07-10 Initiated Coverage Barclays Overweight
2014-07-07 Initiated Coverage Roth Capital Buy $34.00
2014-05-23 Boost Price Target Credit Suisse $35.00 to $40.00
2014-02-27 Initiated Coverage B. Riley Buy
2014-02-18 Boost Price Target Credit Suisse $24.00 to $35.00
2014-01-30 Upgrade JPMorgan Chase & Co. Overweight
2013-11-08 Boost Price Target Wedbush Outperform $31.00 to $35.00
2013-11-08 Boost Price Target Evercore ISI Overweight $30.00 to $34.50
2013-09-23 Reiterated Rating Wedbush Buy
2016-05-06 Reiterated Rating Jefferies Group Hold $8.00
2016-05-06 Reiterated Rating Credit Suisse Buy
2016-05-06 Reiterated Rating Credit Suisse Group AG Buy
2016-04-18 Reiterated Rating RBC Capital Sector Perform $9.00
2016-04-18 Reiterated Rating Royal Bank Of Canada Sector Perform $9.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
HBM Healthcare Investments (Cayman) Ltd. 8.12%  (2441504) OPHT / PTCT / TSPT /
Koppel Adam 7.76%  (2333333) BIIB / DRNA / PTCT / TRVN /
CREDIT SUISSE AG/ Former 10% Owner 7.51%  (2256882) AFFY / PTCT / STRI / WD /
Vulcan Ventures Inc. 2.67%  (803067) ADNC / PTCT /
Hirawat Claudia de Oliveira Ribeiro President 0.13%  (39247) PTCT /
Kovacs Shane William Charles Chief Financial Officer 0.13%  (37850) PTCT /
Rothera Mark Chief Commercial Officer 0.11%  (33739) AEGR / PTCT /
Boulding Mark Elliott Exec. VP, and CLO 0.09%  (27034) PTCT /
Peltz Stuart Walter Chief Executive Officer 0.09%  (26646) PTCT /
Graham Dawn 0.08%  (25000) ECYT / MDVN / PTCT / XENE /
SOUTHWELL DAVID P 0.08%  (23604) PTCT / RCKT / TCRD /
Bolte Axel 0.07%  (20000) OPHT / PTCT /
Jacobson Allan Steven 0.02%  (6848) PTCT /
Utter Christine Marie Principal Financial Officer 0.02%  (6660) PTCT /
Ong Tuyen Chief Medical Officer 0.02%  (6000) PTCT /
Almstead Neil Gregory Senior VP, Research and CMC 0.02%  (5125) PTCT /
Spiegel Robert J. Chief Medical Officer 0.01%  (3239) CAPS / GERN / PTCT / SCMP /
Kranda Michael L 0.01%  (2242) PTCT /
Souza Marcio Chief Operating Officer 0.01%  (1742) PTCT /